SRPT
Sarepta·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SRPT
Sarepta Therapeutics, Inc.
A commercial-stage biopharmaceutical company focused on unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities
215 First Street, Suite 415, Cambridge, MA 02142
--
Sarepta Therapeutics, Inc., was incorporated in Oregon on July 22, 1980. The company is a commercial-stage biopharmaceutical company focused on helping patients by discovering and developing unique RNA-targeted therapies, gene therapies and other gene therapy models for the treatment of rare diseases. Applying their proprietary, highly differentiated and innovative technologies, and through cooperation with strategic partners, the company has developed several approved products for the treatment of Duchenne muscular dystrophy and is developing potential therapeutic candidates for a wide range of diseases and disorders, including Duchenne, muscular dystrophy of the limb girdle and other diseases related to neuromuscular and central nervous system.
Earnings Call
Q1/2025
Estimate EPS-0.65
Actual EPS-3.42
Estimate Revenue684.12M
Actual Revenue774.90M
Sarepta's 2025 Q1 Earnings Call: Unpacking Contradictions in ELEVIDYS Demand, Sales Expectations, and Manufacturing Capacity
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.48
Actual EPS-0.13
Estimate Revenue337.03M
Actual Revenue399.40M
Sarepta's Q3 2025: Contradictions Emerge on ESSENCE Study and FDA Interaction, Infusion Center Capacity, and Prophylactic Sirolimus Use
Nov 04,2025 06:35
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SRPT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.48, beating expectations. The chart below visualizes how SRPT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SRPT has released its 2025 Q3 earnings report, with revenue of 399.36M, reflecting a YoY change of -14.52%, and net profit of -179.95M, showing a YoY change of -635.38%. The Sankey diagram below clearly presents SRPT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
